| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, General Counsel | SVP, General Counsel
1 company
Ryan Edward Brown last filed a Form 4 in June 2024, as EVP, General Counsel at SRPT. Ryan Edward Brown's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 17,129 shares of SRPT. The SRPT filings lean toward selling, a net 40,957 shares.
Ryan Edward Brown has 13 Form 4 filings on record from March 2021 to June 2024, all as EVP, General Counsel at Sarepta Therapeutics (SRPT), 2021–2024.
The 35 reported transactions were 15 tax withholdings, 8 open-market sales, 6 option or other derivative awards and 4 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $6.5M.
The largest open-market sale was 38,957 shares of SRPT at an average $161.61 on June 25, 2024, about $6.3M. Twelve months later SRPT was down 89%.
1 of the 2 sales since April 2023 was made under a Rule 10b5-1 trading plan; the other was not.
Shares as reported in the last Form 4 for each company; the most recent is from June 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.